Replies to post #584402 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Lykiri,

I accept that correction gladly and take your word for it and that perhaps SOC was not fit for purpose too as biosectinvestor points to. A crossover to treatment could have interrupted long term data even more than just leaving out 17 SOC/placebo patients if it would have happened. Just interesting to see all those SOC censors and yet 232 treatment utilized in all the comparisons. Best wishes.